Affimed's lead candidate shows treatment benefit in early-stage study; investors unimpressed, shares down 27% [Seeking Alpha]
Affimed N.V. (AFMD)
Last affimed n.v. earnings: 11/19 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
affimed.com/investor-relations.php
Company Research
Source: Seeking Alpha
Affimed's lead candidate shows treatment benefit in early-stage study; investors unimpressed, shares down 27%Thinly traded nano cap Affimed N.V. (AFMD-26.9%) slumps on more than a 4x surge in volume on the heels of itsannouncement of interim results from aPhase 1b clinical trial assessing lead candidate AFM13 combined with Merck's KEYTRUDA (pembrolizumab) in patients with relapsed/refractory Hodgkin lymphoma (HL). The data were presented at ASH in Atlanta.Patients receiving the combination experienced an 83% (n=5/6) overall response rate (ORR), above the historical ORR of 58 - 63% for KEYTRUDA alone.On the safety front, one dose-limited toxicity was observed in cohort 3 (the highest dose 7.0 mg/kg) which was an infusion reaction leading to discontinuation. Four Grade 3 (serious) adverse events were reported, three possibly related to AFM13 and KEYTRUDA: nausea, vomiting and the infusion-related reaction.Investors appear disappointed with the slow pace of the 33-subject study. Accordin
Show less
Read more
Impact Snapshot
Event Time:
AFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AFMD alerts
High impacting Affimed N.V. news events
Weekly update
A roundup of the hottest topics
AFMD
News
- Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024GlobeNewswire
- Affimed Announces 1-for-10 Reverse Stock SplitGlobeNewswire
- Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerGlobeNewswire
- Affimed Announces Leadership Change and Organizational RestructuringGlobeNewswire
- Global Natural Killer Cells Therapeutics Research Report 2023: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2022 and 2023-2028 [Yahoo! Finance]Yahoo! Finance
AFMD
Earnings
- 11/14/23 - Beat
AFMD
Sec Filings
- 3/28/24 - Form 6-K
- 3/28/24 - Form 20-F
- 3/11/24 - Form 6-K
- AFMD's page on the SEC website